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Development of a novel method 
for the quantification of tyrosine 39 
phosphorylated α- and β-synuclein in human 
cerebrospinal fluid
Chan Hyun Na1,2,3*, Gajanan Sathe3,9, Liana S. Rosenthal2, Abhay R. Moghekar2, Valina L. Dawson1,2,3,5,6, 
Ted M. Dawson1,2,3,6,7* and Akhilesh Pandey3,4,8,10*
Abstract 
Background: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder. Biomarkers that can 
help monitor the progression of PD or response to disease-modifying agents will be invaluable in making appropriate 
therapeutic decisions. Further, biomarkers that could be used to distinguish PD from other related disorders with PD-
like symptoms will be useful for accurate diagnosis and treatment. C-Abl tyrosine kinase is activated in PD resulting 
in increased phosphorylation of the tyrosine residue at position 39 (Y39) of α-synuclein (α-syn) (pY39 α-syn), which 
contributes to the death of dopaminergic neurons. Because pY39 α-syn may be pathogenic, monitoring pY39 α-syn 
could allow us to diagnose presymptomatic PD and help monitor disease progression and response to treatment. We 
sought to investigate if increased phosphorylation of pY39 α-syn can be detected in the cerebrospinal fluid (CSF) of 
PD patients by targeted mass spectrometry.
Methods: Here, we report a two-step enrichment method in which phosphotyrosine peptides were first enriched 
with an anti-phosphotyrosine antibody followed by a second round of enrichment by titanium dioxide  (TiO2) beads 
to detect EGVLpYVGSK sequence derived from tyrosine 39 region of α- and β-synuclein (αβ-syn). Accurate quantifica-
tion was achieved by adding a synthetic heavy version of pY39 αβ-syn peptide before enzymatic digestion.
Results: Using the developed enrichment methods and optimized parallel reaction monitoring (PRM) assays, we 
detected pY39 αβ-syn peptide in human CSF and demonstrated that the ratio of pY39 αβ-syn to Y39 αβ-syn was 
significantly increased in the CSF of patients with PD.
Conclusions: We anticipate that this optimized two-step enrichment-based PRM detection method will help moni-
tor c-Abl activation in PD patients and can also be used to quantify other phosphotyrosine peptides of low abun-
dance in biological samples.
Keywords: Parkinson’s disease, α-Synuclein, β-Synuclein, Phosphotyrosine, Cerebrospinal fluid, Parallel reaction 
monitoring
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Introduction
Although the exact pathogenic mechanism of PD has yet 
to be established, α-syn is an important mediator, and 
moreover, the phosphorylation of α-syn may contribute 
to the pathogenesis via increased aggregation and tox-
icity [1, 2]. Recently, pY39 α-syn has been shown to be 
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closely correlated to disease severity and progression [1, 
3, 4]. Thus, pY39 α-syn levels in the brain could poten-
tially serve as a marker for presymptomatic diagnosis, 
disease progression, and therapeutic response. Since 
pY39 α-syn is increased in the brain of PD patients, we 
postulated that this increased phosphorylation could be 
reflected in the CSF [5].
For targeted detection and quantitation of known 
proteins or post-translational modifications (PTMs) on 
those proteins, PRM mass spectrometry (PRM-MS) has 
been widely used [6, 7]. To quantify pY39 α-syn using 
PRM-MS, pY39 αβ-syn peptide, EGVLpYVGSK will be 
monitored. Although pY39 αβ-syn peptide is shared 
between α-syn and β-syn, we reasoned that the peptide 
can still serve as a PD biomarker unless the phospho-
rylation level of β-syn changes to the opposite direction 
to that of α-syn in PD. When the abundance of a tar-
get protein is too low, the target protein or the derived 
peptide sometimes can be detected using various 
enrichment methods such as immunoprecipitation or 
affinity purification of target proteins or peptides [8–
10]. Here, we report a method specifically developed to 
detect pY39 αβ-syn peptide in human CSF combining 
an enrichment method with the PRM-MS approach. 
Because the abundance of pY39 αβ-syn in CSF is too 
low to be detected even with a conventional enrich-
ment method, we developed a two-step enrichment 
approach using an anti-phosphotyrosine antibody and 
 TiO2 beads followed by PRM-MS analysis for detection 
and quantitation of pY39 αβ-syn peptide. This method 
allowed us to establish that the ratio of pY39 αβ-syn to 
Y39 αβ-syn peptides in the CSF can serve as a potential 
biomarker for the diagnosis and prognosis of PD. Fur-
thermore, this method is applicable to the extremely 




The CSF specimens were collected from normal pressure 
hydrocephalus (NPH) patients, PD patients or cognitively 
normal healthy control individuals evaluated by investi-
gators at the Johns Hopkins Hospital. The CSF samples 
from NPH patients were used for method optimization. 
The CSF samples from PD or control individuals were 
used to compare pY39 αβ-syn peptide levels between the 
two groups. The individuals who are cognitively normal 
or show PD symptoms were diagnosed after extensive 
clinical and cognitive testing. All PD patients met the UK 
Brain Bank criteria for PD diagnosis [11]. After the col-
lection of CSF samples by lumbar puncture, the samples 
were centrifuged for 10  min at 1500×g, aliquoted, and 
stored at − 80  °C within 1 h of acquisition. The demo-
graphic and clinical characteristics of the PD patients 
and control individuals are shown in Additional file  1: 
Table S1.
Enrichment of pY39 αβ‑syn peptide 
only with anti‑phosphotyrosine antibody
Approximately ~ 5.5  mg of proteins derived from 9  ml 
of CSF were lysed in 4 M urea and 50 mM triethylam-
monium bicarbonate (TEAB) followed by a reduction 
with 10  mM dithiothreitol for 1  h at room tempera-
ture (RT) and alkylation with 30  mM iodoacetamide 
for 30  min at RT in the dark. The proteins were then 
digested with an endoproteinase Lys-C (1:100; Wako 
Chemicals, Richmond, VA) by incubating at RT for 
3 h. Subsequently, trypsin digestion was conducted 
by diluting the urea concentration to 2 M by adding 1 
volume of 50  mM TEAB followed by adding sequenc-
ing-grade trypsin (1:50; Promega, Madison, WI) and 
incubating at 37  °C overnight. The peptide samples 
were desalted with  C18 Sep-Pak (Waters Corpora-
tion, Milford, MA) and freeze-dried. The pY39 αβ-syn 
endogenous peptide (EGVLpYVGSK) was enriched by 
performing phosphotyrosine peptide enrichment with 
PTMScan pY1000 antibody according to the manufac-
turer’s instruction (Cell Signaling Technology, Danvers, 
MA). Briefly, the ~ 2.75  mg of CSF peptides derived 
from 9 ml of CSF was reconstituted in 1.4 ml of immu-
noaffinity purification buffer (IAP, 50  mM MOPS, pH 
7.2, 10  mM  Na2HPO4 and 50  mM NaCl). The peptide 
solution was cleared by centrifugation for 5  min at 
10,000×g at 4  °C, and the supernatant was subject to 
the phosphotyrosine enrichment. After washing 40  µl 
of phosphotyrosine agarose beads three times with 
PBS, the CSF peptide solution was added to the washed 
beads followed by incubation at  4o C for 2 h with rota-
tion. Subsequently, the supernatant was removed, and 
the beads were washed thrice with 1  ml of IAP buffer 
and twice with 1 ml of ice-cold water. The bound phos-
photyrosine peptides were eluted by adding 55  µl of 
0.15% trifluoroacetic acid (TFA) and incubated at RT 
for 10 min. After incubation, the tube was centrifuged 
at 2000×g for 1 min and the solution was transferred to 
a new tube. This elution was repeated once again with 
50 µl 0.15% TFA. Twenty fmol of synthetic heavy (13C6, 
15N2-lysine) pY39 αβ-syn peptide was added followed 
by desalting with  C18 StageTip. The eluted peptides 
were then dried using a SpeedVac followed by reconsti-
tution in 15 µl of 0.1% formic acid prior to mass spec-
trometry analysis.
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Enrichment of pY39 αβ‑syn peptide 
both with anti‑phosphotyrosine antibody and  TiO2 beads
For quantification of pY39 αβ-syn peptides from 1  ml 
(~ 0.6 mg of proteins) of CSF samples from PD patients 
or control samples with both PTMScan pY1000 antibody 
and TiO2, 20 fmol of synthetic heavy pY39 αβ-syn pep-
tide was added to CSF. CSF proteins were lysed in 4 M 
urea and 50  mM TEAB followed by a reduction with 
10 mM dithiothreitol for 1 h at RT and alkylation with 
30  mM iodoacetamide for 30  min at RT in the dark. 
The proteins were then digested with an endoprotein-
ase Lys-C (1:100; Wako Chemicals, Richmond, VA) by 
incubating at RT for 3 h. Sequentially trypsin digestion 
was conducted by diluting the urea concentration to 2 M 
by adding 1 volume of 50  mM TEAB followed by add-
ing sequencing-grade trypsin (1:50; Promega, Madison, 
WI) and incubating at 37 °C overnight. The peptide sam-
ples were desalted with  C18 Sep-Pak (Waters Corpora-
tion, Milford, MA) and freeze-dried. The synthetic heavy 
and endogenous pY39 αβ-syn peptides were enriched by 
performing phosphotyrosine peptide enrichment with 
PTMScan pY1000 antibody according to the manufac-
turer’s instruction with minor modifications (Cell Sign-
aling Technology, Danvers, MA). Briefly, the ~ 0.3  mg 
of CSF peptides derived from 1 ml of CSF was reconsti-
tuted in 200 µl of IAP buffer. The peptide solution was 
cleared by centrifugation for 5 min at 10,000×g at 4  °C 
and the supernatant was subjected to the phosphotyros-
ine enrichment. After washing 20 µl of phosphotyrosine 
agarose beads three times with PBS, the CSF peptide 
solution was added to the washed beads followed by 
incubation at 4  °C for 2  h with rotation. Subsequently, 
the supernatant was removed and the beads were 
washed once with ice-cold water. The bound phospho-
tyrosine peptides were eluted by adding 55  µl of 0.15% 
TFA and incubated at RT for 10 min. After incubation, 
the tube was centrifuged at 2000×g for 1  min and the 
solution was transferred to a new tube. This elution 
was repeated once again with 50 µl 0.15% TFA. The elu-
ate was dried using a SpeedVac and the phosphoryl-
ated peptides were enriched again using  TiO2 beads as 
described previously [12]. Briefly, 0.6 mg of  TiO2 beads 
(Titansphere) resuspended in 40  µl of binding buffer 
(65% acetonitrile (ACN) and 2% TFA) were added to the 
peptides followed by incubation at RT for 20  min with 
shaking at 1400  rpm. The peptides were transferred to 
a  C8 StageTip and centrifuged at 2000×g for 2 min. Two 
hundred µl of the washing buffer (65% ACN and 0.1% 
TFA) was added and centrifuged at 2000×g for 5  min. 
This washing was repeated once again. The phospho-
peptides were eluted by adding 40  µl of elution buffer 
(1%  NH4OH and 40% ACN) and centrifuging at 200×g 
for 2  min. The eluted peptides were then dried using a 
SpeedVac followed by reconstitution in 15 µl of 0.1% for-
mic acid prior to mass spectrometry analysis.
Calculation of the limits of detection and quantification
The limits of detection (LOD) were calculated as: 
LOD = µB + t(1-β) (σB + σS)/√n, where µB is the estimated 
mean of blank samples,  t(1-β) is 95 percentile of the stand-
ard t distribution on f degrees of freedom, σB is the stand-
ard deviation of the blank samples, σS is the standard 
deviation of the low concentration samples, and n is the 
number of replicates. The limits of quantification (LOQ) 
were estimated as 3x LOD [13].
Detection of Y39 αβ‑syn peptide
To normalize the amount of pY39 αβ-syn peptide in 
each sample based on the Y39 αβ-syn peptide present in 
each sample, the amount of Y39 αβ-syn peptide in each 
sample was also measured. Twenty fmol of heavy (13C6, 
15N2-lysine) Y39 αβ-syn peptide (EGVLYVGSK*) for the 
quantification of the endogenous Y39 αβ-syn peptide 
were added to 5 µg of CSF peptides followed by desalting 
with  C18 StageTip and LC–MS/MS analysis.
LC–MS/MS analysis
The prepared peptides were analyzed on an Orbitrap 
Fusion Lumos Tribrid Mass Spectrometer coupled to an 
EASY-nLC 1200 nano-flow liquid chromatography sys-
tem (Thermo Fisher Scientific). The peptides from each 
fraction were reconstituted in 15 μl of 0.1% formic acid 
and loaded onto an Acclaim PepMap100 Nano-Trap Col-
umn (100 μm × 2 cm, Thermo Fisher Scientific) packed 
with 5 μm  C18 particles at a flow rate of 5 μl per min. The 
flow rate employed was 250  nl/min using a linear gra-
dient of 10% to 35% solvent B (0.1% formic acid in 95% 
acetonitrile) over 45 minutes on an EASY-Spray column 
(50  cm × 75  µm ID, Thermo Fisher Scientific) packed 
2  µm  C18 particles (Thermo Fisher Scientific), which 
was fitted with an EASY-Spray ion source operated at a 
voltage of 2.7 kV. Mass spectrometry analysis was com-
pleted in a data-dependent manner with a full scan in 
the mass-to-charge ratio (m/z) range of 350 to 1550 fol-
lowed by targeted MS2. MS1 was measured at a resolu-
tion of 120,000 (at m/z of 200). MS2 scan was acquired 
by fragmenting precursor ions using the higher-energy 
collisional dissociation (HCD) method and detected at 
a mass resolution of 30,000 (at m/z of 200). Automatic 
gain control was set to 500,000 and 100,000 ions for MS1 
and MS2, respectively. The maximum ion injection time 
for MS1 was set to 100 ms. Maximum ion times for MS2 
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were set to 2500 and 500  ms for pY39 and Y39 αβ-syn 
peptides, respectively. HCD normalized collisional 
energy (NCE) was set to 25, if not specified. The precur-
sor isolation window was set to 1.6  m/z. Internal cali-
bration was carried out using the lock mass option (m/z 
445.1200025) from ambient air. For the light and heavy 
pY39 αβ-syn peptides, m/z 516.244 and m/z 520.251 
were monitored, respectively. For the light and the heavy 
Y39 αβ-syn peptides, m/z 476.261 and m/z 480.268 were 
monitored, respectively.
Data analysis
The quantification of relative peptide abundance was per-
formed using Skyline software [14]. The levels of pY39 
αβ-syn were normalized by Y39 αβ-syn peptide.
Results
To detect pY39 αβ-syn peptide in CSF samples, we 
initially tried to detect it directly from the digests of 
CSF samples using PRM but were not able to detect 
it. Subsequently, we tried an enrichment of α-syn pro-
tein using an anti-α-syn antibody or enrichment of 
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Fig. 1 The schematic diagram for the research strategy and the detection of endogenous pY39 αβ-syn peptides. a The experimental strategy 
for pY39 αβ-syn peptide enrichment using an anti-phosphotyrosine antibody. CSF proteins were digested with Lys-C and trypsin followed by 
phosphotyrosine peptide enrichment. To validate the detection of the endogenous pY39 αβ-syn peptide, a heavy pY39 αβ-syn standard peptide 
was added before PRM analysis. The endogenous light and heavy standard pY39 αβ-syn peptides were monitored under PRM mode followed by 
a quantification using Skyline software. b The extracted chromatogram of y ion series from either endogenous or heavy standard pY39 αβ-syn 
peptide
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phosphopeptides using  TiO2 or Immobilized metal 
affinity chromatography (IMAC). However, none of 
these enrichment methods were successful in detect-
ing pY39 αβ-syn peptide. We reasoned that because 
pY39 αβ-syn peptide is a tyrosine-phosphorylated 
peptide, we could further reduce peptide complexity 
by performing phosphotyrosine peptide enrichment 
to remove phosphoserine and phosphothreonine pep-
tides, which constitute the majority of phosphopep-
tides. Using this procedure, we were able to detect the 
endogenous pY39 αβ-syn peptide from 9  ml of CSF 
(Fig.  1a, b). Because 9  ml of CSF is not practical vol-
ume in most cases for biomarker detection, we fur-
ther optimized our methods to reduce the CSF volume 
required for the analysis.
Optimizing the detection of pY39 αβ‑syn peptide
To improve our detection sensitivity, we systematically 
evaluated the effect of HCD NCE energy, ion transfer 
capillary temperature and ESI spray voltage on detection. 
For the HCD NCE evaluation, the HCD NCE value 
was increased from 24 to 32. The pY39 αβ-syn peptide 
showed the highest intensity at 25 of HCD NCE (Fig. 2a). 
Next, we evaluated the temperature of the ion trans-
fer capillary increasing it from 160 to 400  °C and pY39 
αβ-syn peptide showed the highest intensity at 180  °C 
(Fig.  2b). We then evaluated ESI voltage optimization 
by increasing from 1500 to 3000. pY39 αβ-syn peptide 
showed the highest intensity at 3000  V (Fig.  2c). Inter-
estingly, the intensity at 3000 V was > 3.5-fold compared 
to the one observed at 1500 V. Although the HCD NCE 
and the ion transfer capillary temperature did not change 
the intensity of pY39 αβ-syn peptide significantly, the ESI 
voltage seemed to be critical in increasing the sensitiv-
ity. We applied the optimized parameters for the detec-
tion of pY39 αβ-syn peptide except that we opted to use 
2700  V instead of 3000  V for preserving column stabil-
ity. A calibration curve with these optimized parameters 
permitted us to detect the target peptide at sub-attomole 
































































Fig. 2 Optimization of mass spectrometry parameters for pY39 peptide detection. a The relative intensity of the standard pY39 αβ-syn peptide 
with different HCD NCEs. b The relative intensity of the standard pY39 αβ-syn peptide with different ion transfer tube capillary temperatures. c The 
relative intensity of the standard pY39 αβ-syn peptide with different ESI voltages
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respectively. The coefficient of variations (CV) was cal-
culated as 26.19% at 1 attomole, 4.45% at 10 attomoles, 
4.84% at 100 attomoles, 10.03% at 1 femtomole, 4.45% at 
10 femtomoles and 8.93% at 100 femtomoles. The average 
CV of the 6 concentrations was 9.81% (Additional file 2: 
Figure S1).
Development of an enrichment method for pY39 αβ‑syn 
peptides
To detect the pY39 αβ-syn peptide from an even smaller 
volume of CSF, we optimized the enrichment method as 
well. Even after the enrichment of phosphotyrosine pep-
tides, 80–90% of peptides were still non-phosphorylated 
ones interfering with the detection of target peptides. 
Thus, the second step of  TiO2-based phosphopeptide 
enrichment should further remove the non-phospho-
rylated peptides, and thereby, we expected that it would 
increase the sensitivity of detecting target peptides 
(Fig.  3a). Thus, we developed a two-step enrichment 
method by combining the antibody-based phosphoty-
rosine peptide enrichment method with the  TiO2-based 
phosphopeptide enrichment method. To optimize this 
two-step detection method, we first evaluated the ratio of 
phosphotyrosine antibody-conjugated agarose beads to 
the input peptide amount. One femtomole of heavy pY39 
αβ-syn peptide was incubated with various volumes of 
antibody-conjugated beads ranging from 2.5 ul to 80 ul. 
The relative intensity of the heavy pY39 αβ-syn peptide 
showed saturation at 20 µl of the agarose beads (Fig. 3b). 
We next optimized the ratio of  TiO2 beads to input 
peptide amount. For this, 2 femtomoles of heavy pY39 
αβ-syn peptide was incubated with various amounts 
of  TiO2 beads ranging from 0.1 mg to 3.2 mg. The pY39 
αβ-syn peptide showed the highest intensity at 0.8 mg of 
 TiO2 beads (Fig. 3c).
Measurement of pY39 αβ‑syn peptide in CSF samples 
from PD and control individuals
Since the goal of this study was to quantify the endog-
enous pY39 αβ-syn peptide in CSF samples from PD 
patients and control individuals, we applied the opti-
mized mass spectrometry parameters and sample prep-
aration procedure to detect the pY39 αβ-syn peptides 
from 4 PD and 4 control individuals as shown in Fig. 4a. 
To minimize any experimental bias and maximize the 
accuracy of quantification, synthetic heavy pY39 αβ-syn 
peptide was added to all CSF samples at the beginning 
of the sample preparation step [15]. When pY39 αβ-syn 
peptide levels in 1 ml of CSF samples from PD patients 
were compared to the ones from controls, there was no 
statistically significant difference (Fig. 4b and Additional 
files 3: Table S2, 4). Because it is already known that total 
α-syn levels are decreased in PD patients, we postulated 
that the levels of pY39 αβ-syn peptide normalized to the 
ones of Y39 αβ-syn peptide might help distinguish PD 
patients from controls. For this, we first measured the 
Y39 αβ-syn levels by spiking synthetic heavy Y39 αβ-syn 
peptide (Additional file  5: Figure S2). As we expected, 
Y39 αβ-syn peptide in CSF from PD patients showed a 
decreased abundance (Fig.  4c). Most importantly, the 
ratio of pY39 αβ-syn to Y39 αβ-syn peptides in CSF from 
PD patients showed a noticeable increase (2.5 fold) with 
statistical significance (P value = 8.4 × 10−5) (Fig.  4d). 
These results are potentially promising and will have to 
be validated in a larger cohort.
Discussion
In this study, we developed a two-step enrichment 
method to detect endogenous pY39 αβ-syn peptide in 
a sensitive manner from CSF samples using PRM-MS. 
This approach enabled us to detect the phosphorylated 
target peptide present at attomole levels per ml of CSF. 
The enrichment efficiency of phosphotyrosine peptides 
using the anti-phosphotyrosine antibody-conjugated 
beads in the first enrichment was usually < 15% owing 
to non-specifically bound peptides even after 5 washes. 
These non-specifically bound peptides increase the 
noise in PRM-MS experiments thereby reducing the 
detection sensitivity. These non-specifically bound pep-
tides can be removed by more extensive washing but it 
will result in the loss of the target peptide at the same 
time. For this reason, we chose to remove the non-spe-
cifically bound peptides by the second enrichment step 
using  TiO2 beads instead of washing the beads strin-
gently losing the target peptide. Using this strategy, we 
were able to improve the detection sensitivity of the 
target peptide to the level of attomole per ml. While the 
endogenous pY39 αβ-syn peptide levels alone did not 
show a statistically significant difference between PD 
and control CSFs, the relative abundance of pY39 over 
Y39 αβ-syn peptides was strikingly different between 
the two groups with statistical significance. Our results 
suggest that the stoichiometry of tyrosine phosphoryla-
tion on the residue 39 of αβ-syn might be increased in 
patients with PD, although how much phosphorylation 
was derived from α-syn still remains to be elucidated. 
The development of this method now makes it possible 
to test the utility of the pY39 over Y39 αβ-syn peptide 
ratio as a potential readout for c-Abl activity as well. 
In addition, this method is broadly applicable to the 
detection of other phosphotyrosine peptides in biologi-
cal samples with minor modifications.


























































































Fig. 3 Two-step enrichment strategy and the optimization of the two-step enrichment experiment conditions. a The experimental strategy for 
pY39 αβ-syn peptide enrichment using the two-step enrichment approach in which phosphotyrosine peptides were enriched followed by total 
phosphopeptides were enriched using  TiO2 beads. CSF proteins were digested with Lys-C and trypsin. To monitor the enrichment efficiency, heavy 
standard pY39 αβ-syn peptide was added before the two-step enrichment and the enrichments were conducted. The endogenous light and 
heavy standard pY39 αSyn were monitored under PRM mode followed by quantification using Skyline software. b Different volumes of agarose 
beads coupled with anti-phosphotyrosine antibodies were incubated with the target peptides to investigate the best ratio of anti-phosphotyrosine 
agarose beads to the target peptides. c Different amounts of  TiO2 beads were incubated with the target peptides to investigate the best ratio of 
 TiO2 beads to the target peptides
















































































































































Fig. 4 Quantification of pY39 αβ-syn peptide in CSF samples from PD and control individuals. a The experimental strategy for pY39 αβ-syn peptide 
enrichment from PD and control CSFs using the two-step enrichment approach. CSF proteins were digested with Lys-C and trypsin followed by 
the two-step enrichment. To minimize experimental biases, heavy standard pY39 αβ-syn peptide was added before starting the experiment. The 
endogenous light and heavy standard pY39 αβ-syn peptides were monitored under PRM mode followed by quantification using Skyline software. 
b The abundances of pY39 αβ-syn peptide in PD and control CSFs. c The abundances of Y39 αβ-syn peptide in PD and control CSFs. d The relative 
abundance of pY39 to Y39 αβ-syn peptide in PD and control CSFs
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